Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis
LD is effective and well-tolerated with a high potential for tumor control and prolonged duration of time until next treatment, especially in patients with FAP and IA desmoid tumors.
Authors
- Rashmi K Chugh (ORCID: https://orcid.org/0000-0002-4633-6971)
- Scott M. Schuetze (ORCID: https://orcid.org/0000-0002-7167-4163)
- Rodney Dixon Dorand (ORCID: https://orcid.org/0000-0002-8901-6281)
- Victoria Wytiaz (ORCID: https://orcid.org/0000-0003-3052-7455)
- Elizabeth J. Davis (ORCID: https://orcid.org/0000-0001-7626-2435)
- Scott C. Borinstein (ORCID: https://orcid.org/0000-0002-1721-1520)
- Vicki L. Keedy (ORCID: https://orcid.org/0000-0002-7213-7562)
- Sean Cohen
Institutions
- University of Michigan (US)
- Moffitt Cancer Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1080/14737140.2025.2545551
- Primary Topic
- Soft tissue tumor case studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health